#Canada #Quebec #Atopic Dermatitis #Devonian Health #Thykamine™

Devonian Health Group Launches Pediatric Clinical Trial for Thykamine™ Treatment

Devonian Health Group Inc., a leading clinical-stage biopharmaceutical company, has recently received authorization from Health Canada to commence a Phase II/III clinical trial. The focus of this study is on Thykamine™, a botanical prescription product, aimed at treating mild-to-moderate atopic dermatitis in pediatric patients aged between 3 months and 17 years.

The overarching aim of the trial is to compare the effectiveness of Thykamine™ against a placebo over a 12-week period of twice-daily application. In addition to assessing effectiveness, the study will also delve into the safety and tolerability of Thykamine™ among children.

Significance of the Study

This clinical trial marks a critical regulatory achievement for Devonian, as it seeks to establish one of the most tailored clinical development programs for a botanical drug treating pediatric atopic dermatitis. The authorization empowers the company to explore the potential of Thykamine™ across a comprehensive pediatric demographic. Notably, approximately 60% of individuals diagnosed with atopic dermatitis show symptoms within their first year of life, making early intervention essential.

Dr. Charles Lynde, a prominent figure in dermatology, will oversee the clinical trial. His expertise, underscored by extensive contributions to dermatological research and clinical trials, will ensure that the study adheres to the highest scientific standards.

Design of the Clinical Trial

Titled "A 12-Week Multicenter, Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Two Concentrations (0.05% and 0.1%) of PUR 0110 (Thykamine™) Cream in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis,” the trial is structured to compare two different concentrations of the product against a placebo.
The study will include around 306 pediatric patients in total, with the enrollment divided into two key phases: 102 children during Phase II and an additional 204 during Phase III. Participants will be randomly assigned to receive either Thykamine™ Cream (at 0.05% or 0.1% concentration) or a placebo cream.

The primary goal is to ascertain the proportion of patients achieving a significant improvement in their condition by the end of the 12 weeks, as measured by a globally recognized assessment score. Secondary objectives will include monitoring safety and the overall tolerability of Thykamine™.

Safety Oversight and Data Monitoring

To ensure patient safety throughout the trial, an independent Data Safety Monitoring Committee (DSMC) has been established. This committee will continuously assess reported adverse events and can recommend ceasing the study at any point should safety concerns arise.
The trial will initially enroll a cohort of 69 children aged 2 to 17 years, followed by another cohort comprising 33 children aged between 3 months and 2 years. This phased enrollment highlights a commitment to cautious and responsible clinical research, with the decision to continue being informed by safety data from the DSMC.

Building on Adult Trial Success

The launch of the pediatric trial comes on the heels of previous successful trials of Thykamine™ in adults. In these studies, significant clinical efficacy was achieved alongside an excellent safety profile, providing a strong foundation for its progression into pediatric trials.

As the research unfolds, Devonian aims to address one of the most prevalent chronic inflammatory conditions affecting children globally. Atopic dermatitis is not only common but can severely impact the quality of life for affected children and their families. The persistent itching and skin inflammation can lead to increased vulnerability to infections and sleep disturbances.

With Thykamine™, a non-steroidal treatment approach may provide much-needed relief and management options for these young patients, paving the way for better long-term health outcomes.

A Word from Leadership

Dr. André P. Boulet, President and CEO of Devonian, stated: "This authorization marks a pivotal moment for our company and showcases our scientific rigor. We are committed to meeting the medical needs of children suffering from atopic dermatitis and are excited to initiate this broad-reaching clinical program. Moreover, having a distinguished expert like Dr. Lynde leads this effort enhances our confidence in achieving meaningful results for affected patients."

With the initiation of this clinical trial, Devonian Health Group continues to demonstrate its commitment to innovative therapeutic solutions targeting significant medical needs in the pediatric population.